PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA
Clinical trials for PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA explained in plain language.
Never miss a new study
Get alerted when new PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA trials appear
Sign up with your email to follow new studies for PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Four-Drug attack on rare brain cancer shows promise in clinical trial
Disease control Recruiting nowThis study is testing whether adding two newer drugs (sintilimab and pirtobrutinib) to standard chemotherapy (methotrexate and rituximab) works better for people with newly diagnosed primary central nervous system lymphoma (PCNSL), a rare brain cancer. Researchers will compare th…
Matched conditions: PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA
Phase: PHASE2 • Sponsor: Tongji Hospital • Aim: Disease control
Last updated Apr 01, 2026 14:42 UTC
-
Early trial tests new hope for Tough-to-Treat brain cancers
Disease control Recruiting nowThis early-stage study is testing whether combining two drugs, epcoritamab and ibrutinib, is safe for people with lymphoma that has returned in or spread to the brain after prior treatment. The main goal is to find a dose that causes few or manageable side effects. It will includ…
Matched conditions: PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA
Phase: PHASE1 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Mar 31, 2026 12:11 UTC
-
Early trial tests Immune-Boosting drug for rare brain cancer
Disease control Recruiting nowThis early-stage study is testing whether adding pembrolizumab, an immunotherapy drug, to standard chemotherapy helps treat primary central nervous system lymphoma, a rare cancer that starts in the brain or spinal cord. The study will enroll about 15 adults with newly diagnosed d…
Matched conditions: PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA
Phase: PHASE1 • Sponsor: Dana-Farber Cancer Institute • Aim: Disease control
Last updated Mar 30, 2026 14:33 UTC
-
New immune therapy targets brain cancer in early trial
Disease control Recruiting nowThis early-stage study is testing the safety and side effects of a new two-part drug treatment for lymphoma that has spread to the brain or spinal cord. The treatment involves an antibody called glofitamab, which is designed to help the body's own immune cells find and attack the…
Matched conditions: PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA
Phase: PHASE1 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated Mar 27, 2026 12:38 UTC
-
New Triple-Threat attack on tough brain cancer
Disease control Recruiting nowThis study is testing a combination of three drugs (pembrolizumab, ibrutinib, and rituximab) for adults with primary central nervous system lymphoma (PCNSL) that has returned or not responded to prior treatment. The goal is to see if this combination can control the cancer and st…
Matched conditions: PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA
Phase: PHASE1, PHASE2 • Sponsor: Dana-Farber Cancer Institute • Aim: Disease control
Last updated Mar 25, 2026 14:07 UTC
-
New hope for tough brain cancer: trial tests powerful drug cocktail
Disease control Recruiting nowThis study is testing a new combination of drugs for a rare and aggressive brain cancer called primary central nervous system lymphoma. The main goal is to find the safest and most effective dose of a targeted drug called ibrutinib when given with a specific chemotherapy regimen.…
Matched conditions: PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 23, 2026 15:15 UTC
-
New drug duo tested in fight against tough brain cancers
Disease control Recruiting nowThis study is testing whether combining two drugs, zanubrutinib and pemetrexed, can help control brain lymphomas that have come back or not responded to previous treatments. It will involve about 15 patients to first check safety and then see how well the treatment works to shrin…
Matched conditions: PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA
Phase: PHASE2 • Sponsor: Baptist Health South Florida • Aim: Disease control
Last updated Mar 16, 2026 15:25 UTC
-
New pill aims to turn immune system against tough blood cancers
Disease control Recruiting nowThis early-stage study is testing a new oral medication called Q702 for patients with advanced blood cancers and rare immune cell disorders that have not responded to standard treatments. The main goals are to find the safest dose and see what side effects occur. Researchers hope…
Matched conditions: PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA
Phase: PHASE1 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated Mar 12, 2026 13:52 UTC